Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: May 2010

20 - Treatment of opioid dependence

from Part III - Specific treatments

Summary

Editor's note

Opiate addiction is one misuse and dependence disorder for which we have good pharmacological treatments. Both methadone and buprenorphine are effective in withdrawing individuals from opiates via substitution, and their use in maintenance treatment has an excellent track record. Naltrexone may also be efficacious for selected patients. Psychosocial and behavioral treatments play a role too, most often in combination with pharmacological treatments or for patients who do not want pharmacological treatments. This is one subject in which practice varies enormously in different parts of the world. Readers who look at the text closely will notice considerable geographical variation in treatment polices, and it is a tribute to our authors that they have kept this to a minimum in this combined chapter.

Introduction

Opioid dependence is a chronic disorder characterized by relapse, increased mortality, significant medical morbidity, psychiatric sequelae and impaired social function in the individual. Accompanying these detrimental effects to the dependent individual are costs to their families and society secondary to impaired social and occupational functioning and increased criminal behavior or violence. In recent years there have been considerable gains in our understanding of the neurobiology of opioid dependence and in the development of new pharmacological and behavioral treatments for opioid dependence.

Epidemiology

In 1999 there were estimated to be 1 million chronic users of heroin in the United States, or 0.4% (4 per 1000) of the population (Rhodes et al., 2000).

REFERENCES
Akram, G. (2000). Over-the-counter medcines: and emerging and neglected drug abuse?. Journal of Substance Use, 5, 136–42.
Amato, L., Davoli, M., Ferri, M., Gowing, L. & Perucci, C. A. (2004). Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug and Alcohol Dependence, 73, 219–26.
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington, DC: American Psychiatric Association.
Archie, C. (1998). Methadone in the management of narcotic addiction in pregnancy. Obstetrics and Gynecology, 10, 435–40.
Auriacombe, M., Franques, P., Daulouede, J. P. & Tignol, J. (1999). The French experience: results from extensive delimited research studies and nation-wide sample surveys. Research and Clinical Forums, 21, 9–15.
Avants, S. K., Margolin, A., Kosten, T. R., Rounsaville, B. J. & Schottenfeld, R. S. (1998). When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. Journal of Consulting Clinical Psychology, 66(6), 924–31.
Avants, S. K., Margolin, A., Sindelar, J. L.et al. (1999). Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. American Journal of Psychiatry, 156(1), 27–33.
Banbery, J., Wolff, K. & Raistrick, D. (2000). Dilhydrocodeine: a useful tool in the detoxification of methadone-maintained patients. Journal of Substance Abuse Treatment, 19, 301–5.
Barnett, P. G., Rodgers, J. H. & Bloch, D. A. (2001). A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction, 96, 683–90.
Barrau, K., Thirion, X., Micallef, J., Chuniaud, L. C., Bellemin, B. & San-Marco, J. L. (2001). Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction, 96, 1433–41.
Bates, M. & Pemberton, D. A. (1996). The effect of methadone prescribing in a clinic setting on the criminal activity of drug users. Scottish Medical Journal, 41, 173–5.
Battersby, M., Farrell, M., Gossop, M., Robson, P. & Strang, J. (1992). ‘Horse trading’: prescribing injectable opiates to opiates addicts. A descriptive study. Drug and Alcohol Review, 11, 35–42.
Bearn, J., Gossop, M. & Strang, J. (1996). Randomised double-blind comparison of lofexidine and methadone in the inpatient treatment of opiate withdrawal. Drug and Alcohol Dependence, 43, 87–91.
Bell, J., Mattick, R., Hay, A., Chan, J. & Hall, W. (1997). Methadone maintenance and drug-related crime. Journal of Substance Abuse, 9, 15–25.
Berghella, V., Lim, P. J., Hill, M. K., Cherpes, J., Chennat, J. & Kaltenbach, K. (2003). Maternal methadone dose and neonatal withdrawal. American Journal of Obstetrics and Gynecology, 189(2), 312–17.
Bertschy, G. (1995). Methadone maintenance treatment: an update. European Archives of Psychiatry and Clinical Neuroscience, 245, 114–24.
Beswick, T., Best, D., Bearn, J., Gossop, M., Rees, S. & Strang, J. (2003). The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomised and placebo-controlled trial. American Journal on Addictions, 12, 295–305.
Buster, M. C. A., Brussel, G. H. A. & Brink, W. (2002). An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction, 97, 993–1001.
Caplehorn, J. R., Dalton, M. S., Haldar, F., Petrenas, A. M. & Nisbet, J. G. (1996). Methadone maintenance and addicts' risk of fatal heroin overdose. Substance Use and Misuse, 31(2), 177–96.
Carnwath, T. & Hardman, J. (1998). Randomised double-blind comparison of lofexdine and clonidine in the out-patient treatment of opiate withdrawal. Drug and Alcohol Dependence, 50, 251–4.
Carreno, J. E., Alvarez, C. E., San Narciso, G. I., Bascaran, M. T., Diaz, M. & Bobes, J. (2003). Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology, 8, 429–38.
Carroll, K. M., Ball, S. A., Nich, C.et al. (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Archives of General Psychiatry, 58(8), 755–61.
Carroll, K. M., Sinha, R., Nich, C., Babuscio, T. & Rounsaville, B. J. (2002). Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Experimental Clinical Psychopharmacology, 10(1), 54–63.
Comer, S. D., Collins, E. D., Kleber, H. D., Nuwayser, E. S., Kerrigan, J. H. & Fischman, M. W. (2002). Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology, 159, 351–60.
Corkery, J. M., Schifano, F., Ghodse, A. H. & Oyefeso, A.. (2004) The effects of methadone and its role in fatalities. Human Psychopharmacology, 19(8), 565–76.
Cornish, J. W., Metzger, D., Woody, G. E., et al. (1997). Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment, 14(6), 529–34.
Croop, R. S., Faulkner, E. B. & Labriola, D. F. (1997). The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group in Archives of General Psychiatry, 54(12), 1130–5.
Curran, H. V., Bolton, J., Wanigaratne, S. & Smyth, C. (1999). Additional methadone increases craving for heroin: a double blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction, 94, 665–74.
Davids, E. & Gastpar, M. (2004). Buprenorphine in the treatment of opioid dependence. European Neuropsychopharmacology, 14, 209–16.
Dawe, S., Griffiths, P., Gossop, M. & Strang, J. (1991). Should opiate addicts be involved in controlling their own detoxification? A comparison of fixed versus negotiable schedules. British Journal of Addiction, 86, 977–82.
Department of Health (1999). Drug Misuse and Dependence – Guidelines on Clinical Management. London: The Stationery Office.
Diamant, K., Fischer, G., Schneider, C.et al. (1998). Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation. European Addiction Research, 4, 198–202.
Dole, V. P., Robinson, J. W., Orraca, J., Towns, E., Searcy, P. & Caine, E. (1969). Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine, 280, 1372–5.
Drug Addiction Treatment Act of 2000, Pub. L. No. 106–310 (October 17, 2000).
Eggen, A. E. & Andrew, M. (1994). Use of codeine analgesics in a general population. A Norwegian study of moderately strong analgesics. European Journal of Clinical Pharmacology, 46, 491–6.
Eklund, C., Melin, L., Hiltunen, A. J. & Borg, S. (1994). Detoxification from methadone maintenance treatment in Sweden: long-term outcome and effects on quality of life and life situation. The International Journal of the Addictions, 29, 627–45.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2000). Insights: reviewing current practice in drug-substitution treatment. Luxembourg: The European Union Office for Official Publications of the European Communities.
Faggiano, F., Vigna-Taglianti, F., Versino, E. & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. In Cochrane Database Systematic Review, 3, CD002208. Oxford: Update Software Ltd.
Fals-Stewart, W. & O'Farrell, T. J. (2003). Behavioral family counseling and naltrexone for male opioid-dependent patients. Journal of Consulting Clinical Psychology, 71(3), 432–42.
Farre, M., Mas, A., Torrens, M., Moreno, V. & Cami, J. (2002). Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug and Alcohol Dependence, 65, 283–90.
Fiellin, D. A., O'Connor, P. G., Chawarski, M., Pakes, J. P., Pantalon, M. V. & Schottenfeld, R. S. (2001). Methadone maintenance in primary care: a randomized controlled trial. Journal of the American Medical Association, 286(14), 1724–31.
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M. & Schottenfeld, R. S. (2002). Treatment of heroin dependence with buprenorphine in primary care. American Journal of Drug and Alcohol Abuse, 28(2), 231–41.
Fischer, G., Gombas, W., Eder, H.et al. (1999). Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 94, 1337–47.
Galanter, M., Dermatis, H., Glickman, L.et al. (2004). Network therapy: decreased secondary opioid use during buprenorphine maintenance. Journal of Substance Abuse Treatment, 26(4), 313–18.
Alonso, Garcia F., Gutierrez, M., San, L.et al. (1989). A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug and Alcohol Dependence, 23, 117–21.
Geerlings, P. J., Bos, T. W., Schalken, H. F. A. & Wouters, L. F. J. M. (1985). Detoxification of heroin addicts with electrostimulation or methadone. Tijdschrift voor Alcohol, Drugs en Andere Psychotrope Stoffen, 11, 80–5.
Gerra, G., Ferri, M., Polidori, E., Santoro, G., Zaimovic, A. & Sternieri, E. (2003). Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. Journal of Substance Abuse Treatment, 25, 1–8.
Giacomuzzi, S. M., Riemer, Y., Ertl, M.et al. (2003). Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction, 98, 693–702.
Gilman, S. M., Galanter, M. & Dermatis, H. (2001). Methadone anonymous: a 12-step program for methadone maintained heroin addicts. Substance Abuse, 22(4), 247–56.
Gossop, M., Johns, A. & Green, L. (1986). Opiate withdrawal: inpatient versus outpatient programmes and preferred versus random assignment to treatment. British Medical Journal, 293, 103–4.
Gossop, M., Marsden, J., Stewart, D. & Rolfe, A. (2000). Patterns of improvement after methadone treatment: one year follow-up results from the National Treatment Outcome Research Study (NTORS). Drug and Alcohol Dependence, 60, 275–86.
Gossop, M., Marsden, J., Stewart, D. & Treacy, S. (2001). Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence, 62, 255–64.
Gossop, M., Marsden, J., Stewart, D. & Kidd, T. (2003) The National Treatment Outcome Research Study (NTORS): 4–5 year follow-up results. Addiction, 98, 291–303.
Gowing, L., Ali, R. & White, J. (2001). Opioid antagonists under sedation or anaesthesia for opioid withdrawal. Cochrane Database Systematic Reviews, 1, CD002022. Oxford: Update Software Ltd.
Guichard, A., Lert, F., Calderon, C.et al. (2003). Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction, 98, 1585–97.
Gunne, L. M. & Gronbaldh, L. (1981). The Swedish methadone maintenance program: a controlled study. Drug and Alcohol Dependence, 7, 249–56.
Gutierrez, M., Ballesteros, J., Gonzalez-Oliveros, R. & Apodaka, J. R. (1995). Retention rates in to naltrexone programmes for heroin addicts in Vitoria, Spain. European Psychiatry, 10, 183–8.
Hamilton, R. J., Olmedo, R. E., Shah, S.et al. (2002). Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine, 9, 63–8.
Hatsukami, D. K. & Fischman, M. W. (1996). Crack cocaine and cocaine hydrochloride: are the differences myth or reality?. Journal of the American Medical Association, 276, 1580–8.
Herve, S., Riachi, G., Noblet, C.et al. (2004). Acute hepatitis due to buprenorphine administration. European Journal of Gastroenterology and Hepatology, 16(10), 1033–7.
Hiltunen, A. J. & Eklund, C. (2002). Withdrawal from methadone maintenance treatment. Reasons for not trying to quit methadone. European Addiction Research, 8, 38–44.
Howells, C., Allen, S., Gupta, J., Stillwell, G., Marsden, J. & Farrell, M. (2002). Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug and Alcohol Dependence, 67, 169–76.
Hser, Y. I., Hoffman, V., Grella, C. E.et al. (2001). A 33-year follow-up of narcotic addicts. Archives of General Psychiatry, 58, 503–8.
Hulse, G. K. & Basso, M. R. (1999). Reassessing naltrexone maintenance as a treatment for illicit heroin users. Drug and Alcohol Review, 18, 263–9.
Iribarne, C., Dreano, Y., Bardou, L. G., Menez, J. F. & Berthou, F. (1997). Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology, 117(1), 13–23.
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A. & Bigelow, G. E. (1995). A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug and Alcohol Dependence, 40, 17–25.
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L. & Bigelow, G. E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medcine, 343(18), 1290–7.
Johnston, L. D., O'Malley, P. M., Bachman, J. G. & Schulenberg, J. E. (2004). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2003 (NIH Publication No. 04–5506). Bethesda, MD: National Institute on Drug Abuse, 59 pp.
Justo, D., Gal-Oz, A., Paran, Y.et al. (2006). Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction, 101, 1333–8.
Kahn, A., Mumford, J. P., Ash-Rogers, G. & Beckford, H. (1997). Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts. Drug and Alcohol Dependence, 44, 57–61.
Kakko, J., Svanborg, K. D., Kreek, M. J. & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet, 361, 662–8.
Keen, J., Oliver, P., Rowse, G. & Mathers, N. (2003). Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?. British Journal of General Practice, 53, 461–7.
King, V. L., Stoller, K. B., Hayes, M.et al. (2002). A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence, 65(2), 137–48.
Kirchmayer, U., Davoli, M., Verster, A. D., Amato, L., Ferri, M. & Perucci, C. A. (2002). A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction, 97, 1241–9.
Kleber, H. D. (1998). Ultrarapid opiate detoxification. Addiction, 92, 1929–33.
Kornick, C. A., Kilborn, M. J., Santiago-Palma, J.et al. (2003). QTc interval prolongation associated with intravenous methadone. Pain, 105(3), 499–506.
Kosten, T. R. (2003). Buprenorphine for opioid detoxification: a brief review. Addictive Disorders and Their Treatment, 2, 107–12.
Kraft, M. K., Rothbard, A. B., Hadley, T. R., McLellan, A. T. & Asch, D. A. (1997). Are supplementary services provided during methadone maintenance really cost-effective?. American Journal of Psychiatry, 154(9), 1214–19.
Kraigher, D., Ortner, R., Eder, H., Schindler, S. & Fischer, G. (2002). Slow-release morphine hydrochloride for maintenance therapy of opioid dependence. Wiener Klinische Wochenschrift, 114, 904–10.
Krantz, M. J., Kutinsky, I. B., Robertson, A. D. & Mehler, P. S. (2003). Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy, 23(6), 802–5.
Kraus, L., Augustin, R., Frischer, M., Kummler, P., Uhl, A. & Wiessing, L. (2003). Estimating prevalence of problem drug use at national level in countries of the European Union and Norway. Addiction, 98, 471–85.
Krupitsky, E. M., Zvartau, E. E., Masalov, D. V.et al. (2004). Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 26(4), 285–94.
Kuschel, C. A., Austerberry, L., Cornwell, M., Couch, R. & Rowley, R. S. (2004). Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?. Archives of Diseases Child and Fetal Neonatal Education, 89(5), F390–3.
Lacroix, I., Berrebi, A., Chaumerliac, C., Lapeyre-Mestre, M., Montastruc, J. L. & Damase-Michel, C. (2004). Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction, 99, 209–14.
Langrod, J., Lowinson, J. & Ruiz, P. (1981). Methadone treatment and physical complaints: a clinical analysis. International Journal of Addiction, 16(5), 947–52.
Ling, W. & Wesson, D. R. (2003). Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug and Alcohol Dependence, 70(2 Suppl), S49–57.
Ling, W., Wesson, D. R., Charuvastra, C. & Klett, C. J. (1996). A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry, 53, 401–7.
MacLeod, J., Whittaker, A. & Robertson, J. R. (1998). Changes in opiate treatment during attendance at a community drug service: findings from a clinical audit. Drug and Alcohol Review, 17, 19–25.
Magura, S., Nwakeze, P. C., Kang, S. Y., & Demsky, S. (1999). Program quality effects on patient outcomes during methadone maintenance: a study of 17 clinics. Substance Use and Misuse, 34(9), 1299–324.
Marsch, L. A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behaviour and criminality: a meta-analysis. Addiction, 93, 515–32.
Masson, C. L., Barnett, P. G., Sees, K. L.et al. (2004). Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction, 99(6), 718–26.
Matheson, C., Pitcairn, J., Bond, C. M., Teijlingen, E. & Ryan, M. (2003). General practice management of illicit drug users in Scotland: a national survey. Addiction, 98, 119–26.
Mattick, R. P., Breen, C., Kimber, J. & Davoli, M. (2002a). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Systematic Reviews, 4, CD002209. Oxford: Update Software Ltd.
Mattick, R. P., Kimber, J., Breen, C. & Davoli, M. (2002b). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Systematic Reviews, 4. Oxford: Update Software Ltd.
McGregor, C., Ali, R., White, J. M.et al. (2002). A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug and Alcohol Dependence, 68, 5–14.
McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E. & O'Brien, C. P. (1993). The effects of psychosocial services in substance abuse treatment. Journal of the American Medical Association, 269(15), 1953–9.
Merrill, J., Alterman, A., Cacciola, J. & Rutherford, M. (1999). Prior treatment history and its impact on criminal recidivism. Journal of Substance Abuse Treatment, 17, 313–19.
Metrebian, N., Shanahan, W., Wells, B. & Stimson, G. V. (1998). Feasibility of prescribing injectable heroin and methadone to opiate dependent drug users: associated health gains and harm reductions. Medical Journal of Australia, 168, 596–600.
Metrebian, N., Shanahan, W., Stimson, G. V.et al. (2001). Prescribing drug of choice to opiate dependent drug users: a comparison of clients receiving heroin with those receiving injectable methadone at a West London drug clinic. Drug and Alcohol Review, 20, 267–76.
Metrebian, N., Carnwath, T., Stimson, G. V. & Storz, T. (2002). Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction, 97, 1155–61.
Metzger, D. S., Woody, G. E., McLellan, A. T.et al. (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18 month prospective follow-up. Journal of Acquired Immune Deficiency Syndrome, 6, 1049–56.
Miller, W. R. & Rollnick, S. (1991). Motivational Interviewing: Preparing People for Change, 2nd edn. New York: Guilford Press.
Montoya, I. D., Gorelick, D. A., Preston, K. L.et al. (2004). Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical and Pharmacological Therapy, 75(1), 34–48.
Newman, R. G. & Whitehill, W. B. (1979). Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet, 2, 485–8.
Nyswander, M., Winick, C., Bernstein, A., Brill, L. & Kaufer, G. (1958). Treatment of the narcotic addict: workshop, 1957. 1. The treatment of drug addicts as voluntary outpatients; a progress report. American Journal of Orthopsychiatry, 28(4), 714–27; discussion 727–9.
O'Connor, P. G. & Kosten, T. R. (1998). Rapid and ultrarapid opioid detoxification techniques. Journal of the American Medical Association, 279, 229–234.
O'Connor, P. G., Oliveto, A. H., Shi, J. M.et al. (1998). A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine, 105(2), 100–5.
O'Malley, J. E., Anderson, W. H. & Lazare, A. (1972). Failure of outpatient treatment of drug abuse. I. Heroin. American Journal of Psychiatry, 128(7), 865–8.
O'Malley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E. & Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Archives of General Psychiatry, 49, 881–7.
Pates, R., McBride, A., Li, S. & Ramadan, R. (2002). Misuse of over-the-counter medicines: a survey of community pharmacies in a South Wales health authority. The Pharmaceutical Journal, 268, 179–82.
Petitjean, S., Stohler, R., D-glon, J.et al. (2001). Double-blind randomised trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence, 62, 97–104.
Poirier, M. F., Laqueille, X., Jalfre, V.et al. (2004). Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicentre study of 73 patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 267–72.
Preston, K. L., Silverman, K., Umbricht, A., DeJesus, A., Montoya, I. D., & Schuster, C. R. (1999). Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Dependence, 54(2), 127–35.
Ravndal, E. (2001). An outcome study of a therapeutic community based in the community: a five-year prospective study of drug abusers in Norway In Therapeutic Communities, 4th edn. Rawlings, B. & Yates, R., pp. 224–240. Philadelphia: Jessica Kingsley Publishers.
Ravndal, E. & Vaglum, P. (1991). Psychopathology and substance abuse as predictors of program completion in a therapeutic community for drug abusers: a prospective study. Acta Psychiatrica Scandinavica, 83, 217–22.
Rehm, J., Gschwend, P., Steffen, T., Gutzwiller, F., Dobler-Mikola, A. & Uchtenhagen, A. (2001). Feasibility, safety and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet, 358, 1417–20.
Rhodes, W., Layne, M., Johnston, P., & Hozik, L. (2000). What America's Users Spend on Illegal Drugs, 1988–1998. Office of National Drug Control Policy.
Ribeaud, D. (2004). Long-term impacts of the Swiss heroin prescription trials on crime of treated heroin users. Journal of Drug Issues, 34, 163–94.
Riordan, C. E. & Kleber, H. D. (1980). Rapid opiate detoxification with clonidine and naloxone (letter). Lancet, 1(8177), 1079–80.
Roozen, H. G., Boulogne, J. J., Tulder, M. W., Brink, W. & Jong, C. A. J. (2004). A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug and Alcohol Dependence, 74, 1–13.
Roset, P., Farre, M., Torre, R.et al. (2001). Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Dependence, 64, 285–98.
Roth, A., Hogan, I. & Farren, C. (1997). Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. Journal of Substance Abuse Treatment, 14(1), 19–22.
Rounsaville, B. J. (1995). Can psychotherapy rescue naltrexone treatment of opioid addiction?. NIDA Research Monograph, 150, 37–52.
Rounsaville, B. J., Glazer, W., Wilber, C. H., Weissman, M. M. & Kleber, H. D. (1983). Short-term interpersonal psychotherapy in methadone-maintained opiate addicts. Archives of General Psychiatry, 40, 629–36.
Rothenberg, J. L., Sullivan, M. A., Church, S. H.et al. (2002). Behavioral naltrexone therapy: an integrated treatment for opiate dependence. Journal of Substance Abuse Treatment, 23(4), 351–60.
Salsitz, E. A., Joseph, H., Frank, B.et al. (2000). Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice – a summary report (1983–1998). Mount Sinai Journal of Medicine, 67(5–6), 388–97.
San, L., Pomarol, G., Peri, J. M., Olle, J. M. & Cami, J. (1991). Follow-up after a 6-month maintenance period on naltrexone versus placebo in heroin addicts. British Journal of Addiction, 86, 983–90.
Saunders, B., Wilkinson, C. & Phillips, M. (1995). The impact of a brief motivational intervention with opiate users attending a methadone programme. Addiction, 90(3), 415–24.
Schindler, S. D., Eder, H., Ortner, K. R., Rohrmeister, K., Langer, M. & Fischer, G. (2003). Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction, 98, 103–10.
Schottenfeld, R. S., Pakes, J. R., Oliveto, A., Ziedonis, D. & Kosten, T. R. (1997). Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives in General Psychiatry, 54(8), 713–20.
Sees, K. L., Delucchi, K. L., Masson, C.et al. (2000). Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. Journal of the American Medical Association, 283(10), 1303–10.
Seivewright, N. & Lagundoye, O. (2003). Withdrawal from methadone and methadone for withdrawal. In Methadone Matters: Evolving Community Methadone Treatment of Opioid Addiction, ed. Strang, J. & Tober, G., pp. 79–87. London: Martin Dunitz.
Sell, L., Segar, G. & Merrill, J. (2001). One hundred and twenty-five prescriptions for injectable opiates in the North West of England. Drug and Alcohol Review, 20, 57–66.
Sheppard, S. G. (1994). A preliminary investigation of ibogaine: Case reports and recommendations for further study. Journal of Substance Abuse Treatment, 11, 379–85.
Spear, H. B. (2002). Heroin Addiction Care and Control: The British System, 1916–1974, ed. Mott, J.. London: DrugScope.
Stanton, M. D., Todd, T. C. (1982). The Family Therapy of Drug Abuse and Addiction. New York: Guilford Press.
Stella, L., Cassese, F., Barone, S.et al. (1999). Naltrexone to keep a drug-free condition. Research Communications in Alcohol and Substance of Abuse, 20, 91–8.
Stitzer, M. L., Iguchi, M. Y. & Felch, L. J. (1992). Contingent take-home incentive: effects on drug use of methadone maintenance patients. Journal of Consulting Clinical Psychology, 60(6), 927–34.
Strain, E. C., Stitzer, M. L., Liebson, I. A. & Bigelow, G. E. (1994). Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry, 151, 1025–30.
Strain, E. C., Bigelow, G. E., Liebson, I. A. & Stitzer, M. L. (1999). Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. Journal of the American Medical Association, 281, 1000–5.
Strang, J., Finch, E., Hankinson, L., Farrell, M., Taylor, C. & Gossop, M. (1997). Methadone treatment for opiate addiction: benefits in the first month. Addiction Research, 5, 71–6.
Strang, J., Marsden, J., Cummins, M.et al. (2000). Randomised trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. Addiction, 95, 1631–45.
Substance Abuse and Mental Health Services Administration (SAMSHA). (2004). Overview of Findings from the 2003 National Survey on Drug Use and Health. Rockville, MD: NSDUH Series. Office of Applied Studies.
Ter-Riet, G., Kleijnen, J. & Knipschild, P. (1990). A meta-analysis of studies into the effect of acupuncture on addiction. British Journal of General Practice, 40, 379–82.
US Department of Justice, Drug Enforcement Administration: (2003). 2002 Domestic Monitor Program, Drug Intelligence Report. June, DEA-03057.
Uchtenhagen, A., Dobler-Mikola, A. & Gutzwiller, F. (1996). Medical prescription of narcotics: background and intermediate results of a Swiss national project. European Research Journal, 2, 201–7.
Uchtenhagen, A., Gutzweiller, F., Dobler-Mikola, A. & Steffen, A. (1997). A programme for a medical prescription of narcotics. A synthesis of results. European Addiction Research, 3, 160–16.
Uehlinger, C., Deglon, J. J., Livoti, S., Petitjean, S., Waldvogel, D. & Ladewig, D. (1998). Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. European Addiction Research, 4, 13–18.
Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W. J., Zwieten, B. J. & Ree, J. M. (2003). Medial prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. British Medical Journal, 327, 310–12.
Verthein, U., Haasen, C. & Krausz, M. (2002). Auricular acupuncture as a treatment of cocaine, heroin and alcohol addiction: a pilot study. Addictive Disorders and Their Treatment, 1, 11–16.
Volpicelli, J. R.Alterman, A. I.Hayashida, M. & O'Brien, C. P. (1992). Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry, 49, 876–80.
Walsh, S. L. & Eissenberg, T. (2003). The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence, 70, S13–27.
Walsh, S. L., Strain, E. C. & Bigelow, G. E. (2003). Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction, 98(4), 427–39.
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J. & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical and Pharmacological Therapy, 55(5), 569–80.
Washton, A. M., Gold, M. S. & Pottash, A. C. (1984). Successful use of naltrexone in addicted physicians and business executives. Advances in Alcohol Substance Abuse, 4(2), 89–96.
West, S. L., O' Neal, K. K. & Graham, C. W. (2000). A meta-analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse, 12, 405–14.
Williams, H., Remedios, A., Oyefeso, A. & Bennett, J. (2002). Buprenorphine detoxification treatment for heroin dependence: a preliminary experience in an outpatient setting. Irish Journal of Psychological Medicine, 19, 80–3.
Woody, G. E., Luborsky, L., McLellan, A. T.et al. (1983). Psychotherapy for opiate addicts. Does it help?. Archives in General Psychiatry, 40(6), 639–45.
Yandoli, D., Eisler, I., Robbins, C., Mulleady, G. & Dare, C. (2002). A comparative study of family therapy in the treatment of opiate users in a London drug clinic. Journal of Familiy Therapy, 24, 402–22.